Volume Restoration of the Aging Midface With Sculptra Aesthetic

NCT ID: NCT01307865

Last Updated: 2013-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the effect of Sculptra Aesthetic on the cosmetic rejuvenation of the midface complex. The investigators plan to both qualitatively determine the restoration of midface architecture as well as quantitatively document the change in midface volume by employing three-dimensional (3D) surface imaging which critically analyzes volumetric tissue changes. Our hypothesis is that patients who receive Sculptra Aesthetic injections will experience significant improvement in facial midface volume restoration.

* Measure the midfacial volumetric correction from Sculptra Aesthetic treatment, using three-dimensional digital surface imaging
* Determine the mean change from baseline in facial contour via quantitative volumetric measurements
* Correlate volumetric correction with clinical improvement as measured by the Facial Lipoatrophy Panel grading system
* Correlate the mean volumetric change in midfacial treatment area with the amount of product used
* Obtain photographs pre- and post-treatment for the purpose of providing a subject visual aid during the course of treatment
* Collect safety data

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Problem of Aging

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

midface volume loss aging of midface sculptra sculptra aesthetic poly-L-lactic acid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sculptra Aesthetic

Patients receiving Sculptra Aesthetic

Group Type EXPERIMENTAL

injectable poly-L-lactic acid

Intervention Type DRUG

Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

injectable poly-L-lactic acid

Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sculptra Aesthetic Sculptra Poly-L-lactic acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 40-60 years old
* BMI greater than 18.5 and less than 24.9

Exclusion Criteria

* Age less than 40 years or greater than 60 years
* Prior surgical or non-surgical treatment to the midface within the past 2 years
* Interested in seeking other treatments to the midface during the study period
* Pregnant, lactating, or breast feeding
* Hypersensitivity to poly-L-lactic acid, carboxymethylcellulose, or mannitol
* Allergy to lidocaine or epinephrine
* History of atopy, anaphylaxis, or multiple severe allergies
* Current immunotherapy or history of autoimmune disease
* History of or active stroke or myocardial infarction
* History of or active connective tissue disease
* History of or active bleeding disorders
* History of or active cancer
* Serious abnormalities in laboratory findings
* Active hepatitis
* Active infection or inflammatory process of skin
* History of or risk factors for hypertrophic scarring or keloid formation
Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanofi

INDUSTRY

Sponsor Role collaborator

Williams Center Plastic Surgery Specialists

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Edwin F. Williams, III, M.D.

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Edwin F Williams, MD

Role: PRINCIPAL_INVESTIGATOR

Williams Center Plastic Surgery Specialists

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Williams Center Plastic Surgery Specialists

Latham, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Chen HH, Javadi P, Daines SM, Williams EF 3rd. Quantitative assessment of the longevity of poly-L-lactic acid as a volumizing filler using 3-dimensional photography. JAMA Facial Plast Surg. 2015 Jan-Feb;17(1):39-43. doi: 10.1001/jamafacial.2014.867.

Reference Type DERIVED
PMID: 25340593 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EFW-001-SA

Identifier Type: -

Identifier Source: org_study_id